This post is from a suggested group
Hematopoietic Stem Cell Transplantation and Myeloablative Protocols
Hematopoietic stem cell transplantation is a definitive clinical intervention for patients with lethal hematological malignancies or bone marrow failure syndromes. The procedure involves the intravenous infusion of multipotent hematopoietic progenitor cells, which migrate to the marrow space to re-establish functional blood cell production following intensive chemotherapy or total body irradiation.
Successful engraftment requires precise Human Leukocyte Antigen matching to minimize the risk of immunological rejection. Allogeneic grafts, sourced from related or unrelated donors, are screened for histocompatibility to reduce the incidence of graft-versus-host disease, a condition where donor immune cells mount a systemic attack against the recipient’s epithelial and visceral tissues.
[Image of hematopoietic stem cell differentiation in bone marrow] The clinical trajectory of a transplant recipient is divided into several high-risk phases. During the pre-transplant conditioning phase, the patient's existing immune system is suppressed or obliterated to make room for the donor cells. This leads to a profound state…
👑👑👑👑👑